MRgFUS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS: A CLINICAL UPDATE Raul Martinez Fernandez, Centro Integral en Neurociencias A.C. (HM CINAC), Madrid e-mail: rmartinez.hmcinac@hmhospitales.com Since the first studies using MRgFUS for the treatment of essential tremor came out in 2013, its applications for neurological diseases have progressively increased. Today, MRgFUS thalamotomy is a FDA-approved treatment for both essential and parkinsonian tremors and some evidence suggests that it can also be useful for tremors of other origins. Furthermore, ablation of other targets such as the subthalamic nucleus and the internal globus pallidus has preliminary shown to safely provide benefit on all Parkinson’s disease motor features and complications. MRgFUS has also been applied, with initial but promising results, in dystonia or obsessive-compulsive disorder, and has started to experimentally be considered in other neurological conditions like refractory epilepsy or stroke. While the main objective of the mentioned applications is the symptomatic relief, the ability of FUS to transiently and focally open the Blood-Brain Barrier through a physical mechanism, have paved the way to impact on the neurodegenerative process and achieve a disease modifying effect. Accordingly, experimental trials for Parkinson’s disease, Alzheimer dementia and amyotrophic lateral sclerosis are ongoing. This talk will present an overview of the current evidence with focused ultrasound in Neurology, with special attention in movement disorders, the most investigated field so far.